advexin: Clinical Trials

7 trials of advexin, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

3 completed, 2 terminated, 2 unknown. 7 Phase 2, 2 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 27Completed 3, Terminated 2, Unknown 2
Phase 12Completed 1, Terminated 1

Follow advexin: new trials by email Literature Review of advexin trials Research Report on advexin

Trials (filtered) newest first · largest first

All 7 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Safety and Efficacy of Intra-Arterial and Intra-Tumoral Ad-p53 With Capecitabine (Xeloda) or Anti-PD-1 in Liver Metastases of Solid Tumors and Recurrent Head and Neck Squamous Cell Cancer
Ad-P53, Xeloda, Keytruda - Metastatic Solid Tumor Cancer, Recurrent Head and Neck Cancer
Phase 1 / Phase 2TerminatedMultiVir, Inc.42018-11-202020-06-02
Safety and Efficacy of p53 Gene Therapy Combined With Immune Checkpoint Inhibitors in Solid Tumors.
Ad-p53 - Solid Tumor, Lymphoma
Phase 2UnknownMultiVir, Inc.402018-10-012020-06-09
Gene Therapy in Preventing Cancer in Patients With Premalignant Carcinoma of the Oral Cavity or Pharynx
Ad5CMV-p53 gene, laboratory biomarker analysis - Lip and Oral Cavity Cancer, Oropharyngeal Cancer
Phase 1 / Phase 2CompletedNational Cancer Institute (NCI)512003-06-012013-01-23
S0011, Gene Therapy & Surgery Followed by Chemo & RT in Newly Diagnosed Cancer of the Mouth or Throat
Ad5CMV-p53 gene, cisplatin, conventional surgery - Head and Neck Cancer
Phase 2TerminatedSWOG Cancer Research Network132003-02-012012-06-14
Chemotherapy Combined With Gene Therapy in Treating Patients Who Have Stage III or Stage IV Breast Cancer
Ad5CMV-p53 gene, docetaxel, doxorubicin hydrochloride - Breast Cancer
Phase 2CompletedIntrogen Therapeutics2002-02-012013-05-30
Gene Therapy in Treating Patients With Recurrent Head and Neck Cancer
Ad5CMV-p53 gene - Head and Neck Cancer
Phase 2UnknownAventis Pharmaceuticals391998-01-012013-12-04
Study to Determine the Efficacy and Safety of Docetaxel and Doxorubicin With INGN 201 in Locally Advanced Breast Cancer
INGN 201 - Locally Advanced Breast Cancer (LABC)
Phase 2CompletedIntrogen Therapeutics602008-04-01

Conditions studied

Head and Neck Neoplasms (3)  ·  Squamous Cell Carcinoma of Head and Neck (2)  ·  Breast Neoplasms (1)  ·  Breast Neoplasms, Male (1)  ·  Carcinoma (1)  ·  Carcinoma, Merkel Cell (1)  ·  Carcinoma, Non-Small-Cell Lung (1)  ·  Carcinoma, Renal Cell (1)  ·  Carcinoma, Transitional Cell (1)  ·  Esophageal Neoplasms (1)  ·  Hodgkin Disease (1)  ·  Liver Neoplasms (1)  ·  Lymphoma (1)  ·  Melanoma (1)  ·  Mouth Neoplasms (1)

Sponsors

Introgen Therapeutics (2)  ·  MultiVir, Inc. (2)  ·  Aventis Pharmaceuticals (1)  ·  National Cancer Institute (NCI) (1)  ·  SWOG Cancer Research Network (1)

Countries

United States (7)

Top investigators

Gary L. Clayman (1)  ·  George H. Yoo, MD (1)  ·  Jill Van Warthood, PhD (1)  ·  Lyndah Dreiling, MD (1)  ·  Vivek Subbiah, MD (1)

Results publications

PMID 19770418

NIH funding

P50CA097007 (1), U10CA032102 (1)